Using the analytic hierarchy process to elicit patient preferences: prioritizing multiple outcome measures of antidepressant drug treatment.

BACKGROUND AND OBJECTIVE In health technology assessment, the evidence obtained from clinical trials regarding multiple clinical outcomes is used to support reimbursement claims. At present, the relevance of these outcome measures for patients is, however, not systematically assessed, and judgments on their relevance may differ among patients and healthcare professionals. The analytic hierarchy process (AHP) is a technique for multi-criteria decision analysis that can be used for preference elicitation. In the present study, we explored the value of using the AHP to prioritize the relevance of outcome measures for major depression by patients, psychiatrists and psychotherapists, and to elicit preferences for alternative healthcare interventions regarding this weighted set of outcome measures. METHODS Supported by the pairwise comparison technique of the AHP, a patient group and an expert group of psychiatrists and psychotherapists discussed and estimated the priorities of the clinical outcome measures of antidepressant treatment. These outcome measures included remission of depression, response to drug treatment, no relapse, (serious) adverse events, social function, no anxiety, no pain, and cognitive function. Clinical evidence on the outcomes of three antidepressants regarding these outcome measures was derived from a previous benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG; Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen). RESULTS The most important outcome measures according to the patients were, in order of decreasing importance: response to drug treatment, cognitive function, social function, no anxiety, remission, and no relapse. The patients and the experts showed some remarkable differences regarding the relative importance of response (weight patients = 0.37; weight experts  = 0.05) and remission (weight patients = 0.09; weight experts = 0.40); however, both experts and patients agreed upon the list of the six most important measures, with experts only adding one additional outcome measure. CONCLUSIONS The AHP can easily be used to elicit patient preferences and the study has demonstrated differences between patients and experts. The AHP is useful for policy makers in combining multiple clinical outcomes of healthcare interventions grounded in randomized controlled trials in an overall health economic evaluation. This may be particularly relevant in cases where different outcome measures lead to conflicting results about the best alternative to reimburse. Alternatively, AHP may also support researchers in selecting (primary) outcome measures with the highest relevance.

[1]  E. Triantaphyllou,et al.  A Sensitivity Analysis Approach for Some Deterministic Multi-Criteria Decision-Making Methods* , 1997 .

[2]  E. Forman,et al.  Aggregating individual judgments and priorities with the analytic hierarchy process , 1998, Eur. J. Oper. Res..

[3]  Luis G. Vargas,et al.  Decision Making with the Analytic Network Process: Economic, Political, Social and Technological Applications with Benefits, Opportunities, Costs and Risks , 2013 .

[4]  P. Harker Derivatives of the Perron root of a positive reciprocal matrix: With application to the analytic hierarchy process , 1987 .

[5]  B. Bloom Prevalence and economic effects of depression. , 2004, Managed care.

[6]  J. Baron,et al.  Towards Patient-Centered Care for Depression , 2012 .

[7]  M. Susser The epidemiology of life stress , 1981, Psychological Medicine.

[8]  Bertrand Mareschal,et al.  Weight stability intervals in multicriteria decision aid , 1988 .

[9]  Maarten J. IJzerman,et al.  Assessment of the added value of the Twente Photoacoustic Mammoscope in breast cancer diagnosis , 2011, Medical devices.

[10]  B. Gaynes,et al.  Screening for Depression in Adult Patients in Primary Care Settings: A Systematic Evidence Review , 2009, Annals of Internal Medicine.

[11]  C. Sherbourne,et al.  Treatment preferences among depressed primary care patients , 2000, Journal of General Internal Medicine.

[12]  N. Powe,et al.  Identification of patient attitudes and preferences regarding treatment of depression , 1997, Journal of General Internal Medicine.

[13]  Maarten Joost IJzerman,et al.  A Comparison of Analytic Hierarchy Process and Conjoint Analysis Methods in Assessing Treatment Alternatives for Stroke Rehabilitation , 2012, The Patient - Patient-Centered Outcomes Research.

[14]  V. Milanova,et al.  Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR , 2009, Journal of psychopharmacology.

[15]  John Cornell,et al.  A Systematic Review of Newer Pharmacotherapies for Depression in Adults: Evidence Report Summary: Clinical Guideline, Part 2 , 2000, Annals of Internal Medicine.

[16]  L. Cunningham Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression , 1997, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[17]  Maarten Joost IJzerman,et al.  Using the Analytic Hierarchy Process to Elicit Patient Preferences , 2012, The Patient: Patient-Centered Outcomes Research.

[18]  T. Saaty Highlights and critical points in the theory and application of the Analytic Hierarchy Process , 1994 .

[19]  R. D. Holder,et al.  Some Comments on the Analytic Hierarchy Process , 1990 .

[20]  C. Dowrick,et al.  Impact of severity and type of depression on quality of life in cases identified in the community , 2010, Psychological Medicine.

[21]  Gerhard Rakhorst,et al.  The effects of team expert choice on group decision-making in collaborative new product development: a pilot study , 2000 .

[22]  James C. Dolan,et al.  Diagnostic strategies in the management of acute upper gastrointestinal bleeding , 1993, Journal of General Internal Medicine.

[23]  J. Baron,et al.  TOWARDS PATIENT-CENTERED CARE FOR DEPRESSION: CONJOINT METHODS TO TAILOR TREATMENT BASED ON PREFERENCES. , 2010, The patient.

[24]  Maarten J. IJzerman,et al.  Integrating patients' views into health technology assessment: Analytic hierarchy process (AHP) as a method to elicit patient preferences , 2011, International Journal of Technology Assessment in Health Care.

[25]  R. DeRubeis,et al.  Antidepressant drug effects and depression severity: a patient-level meta-analysis. , 2010, JAMA.

[26]  Panos M. Pardalos,et al.  On the Evaluation and Application of Different Scales For Quantifying Pairwise Comparisons in Fuzzy Sets , 1994 .

[27]  P. Masand,et al.  Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. , 2002, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[28]  Thomas L. Saaty,et al.  Multicriteria Decision Making: The Analytic Hierarchy Process: Planning, Priority Setting, Resource Allocation , 1990 .

[29]  Emily Lancsar,et al.  Deleting 'irrational' responses from discrete choice experiments: a case of investigating or imposing preferences? , 2006, Health economics.

[30]  Matthew J. Liberatore,et al.  The analytic hierarchy process in medical and health care decision making: A literature review , 2008, Eur. J. Oper. Res..

[31]  A. Schatzberg,et al.  Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. , 2005, Journal of psychiatric research.

[32]  J. Dolan Multi-Criteria Clinical Decision Support , 2010, The patient.

[33]  John F P Bridges,et al.  Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. , 2003, Applied health economics and health policy.

[34]  Emily Lancsar,et al.  Choice experiments in health: the good, the bad, the ugly and toward a brighter future , 2009, Health Economics, Policy and Law.

[35]  Marjukka Mäkelä,et al.  Volume 26: Statistics and thanks , 2011, International Journal of Technology Assessment in Health Care.

[36]  Ward T. Smith,et al.  Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. , 1990, Psychopharmacology bulletin.